8-K current report · filed Jul 29, 2026

GLAUKOS Corp (GKOS) 8-K Current Report: July 29, 2026

Item 2.02Item EX-99.1Item EX-99.2Item 7.01GKOS overview

Short answer

GLAUKOS Corp (GKOS) filed an 8-K current report with the SEC on July 29, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1), Item EX-99.2 (Exhibit EX-99.2), Item 7.01 (Regulation FD Disclosure). Q2 2026 results for quarter ended June 30, 2026 announced July 29, 2026.

GLAUKOS Corp 8-K event analysis

AI summary of each reported item and its exhibits

Item 2.02 · Results of Operations and Financial Condition

  • Q2 2026 results for quarter ended June 30, 2026 announced July 29, 2026
  • Press release contains the financial results and accompanying investor-relevant details as Exhibit 99.1

Item 7.01 · Regulation FD Disclosure

  • Quarterly Summary covers Glaukos’ second quarter ended June 30, 2026
  • Supplemental business and financial information available in Exhibit 99.2
  • Investor relevance: additional quarterly detail supports analysis beyond the primary earnings disclosure

Item EX-99.1 · Exhibit EX-99.1

  • Q2 net sales $185.6M, up 50% YoY, with glaucoma sales $155.2M and U.S. glaucoma sales $118.5M
  • Gross margin improved to 81.7% from 78.3%; non-GAAP margin reached 84.5%
  • GAAP operating loss narrowed to $17.3M from $22.7M; non-GAAP loss improved to $7.6M
  • 2026 revenue guidance raised to $680M-$700M from $620M-$635M, signaling stronger expected demand
  • $289.3M in cash, investments and restricted cash with no debt, supporting continued commercialization and pipeline investment

Item EX-99.2 · Exhibit EX-99.2

  • Q2 revenue $185.6M, up 50% reported and 49% constant currency, confirming accelerating demand for iDose TR and Epioxa
  • U.S. Glaucoma revenue $118.5M, up 64%, with iDose TR sales approximately $74M
  • Epioxa revenue approximately $11M, with coverage pathways exceeding 125M commercial lives and J-code J2789 effective July 1
  • FY2026 revenue guidance raised to $680M-$700M from $620M-$635M, signaling stronger commercialization momentum
  • Non-GAAP gross margin approximately 85%, while GAAP net loss remained $18.4M, highlighting continued launch and R&D investment

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other GLAUKOS Corp 8-K filings

Get the next GKOS 8-K as it lands

Follow GKOS for push alerts, or ask the research agent what this filing means.